Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
I-BRD9 is a potent and selective BRD9 inhibitor (pIC50 = 7.3). Exhibits >70-fold selectivity for BRD9 over a panel of 34 other bromodomains and >700-fold selectivity over the BET family. Downregulates CLEC1, DUSP6, FES and SAMSN1 genes in Kasumi-1 cells.
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the I-BRD9 probe summary on the SGC website.
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of I-BRD9 is reviewed on the chemical probes website.
I-BRD9 is also offered as part of the Tocriscreen Epigenetics Library. Find out more about compound libraries available from Tocris.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 497.55. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.01 mL||10.05 mL||20.1 mL|
|5 mM||0.4 mL||2.01 mL||4.02 mL|
|10 mM||0.2 mL||1 mL||2.01 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References are publications that support the biological activity of the product.
Theodoulou et al (2015) Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition. J.Med.Chem 59 1425 PMID: 25856009
If you know of a relevant reference for I-BRD9, please let us know.
Keywords: I-BRD9, I-BRD9 supplier, bromodomains, containing, protein, extra, terminal, inhibits, inhibitors, potent, selective, downregulates, downregulation, sgc, structural, genomics, consortium, Bromodomains, 5591, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for I-BRD9 include:
Brien et al (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife 7 e41305 PMID: 30431433
Wei et al (2018) Vitamin D switches BAF complexes to protect β cells. Cell 173 1135 PMID: 29754817
Do you know of a great paper that uses I-BRD9 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review I-BRD9 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.